|
|
|
市場調查報告書
新興的癌症疫苗：預測、開發、管道分析（第4版）
Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition
|
新興的癌症疫苗：預測、開發、管道分析（第4版） 是由出版商Kalorama Information在2010年09月所出版的。
這份英文市場調查報告書包含216 Pages 價格從美金3995起跳。
本報告書以開發中的預防用以及治療用兩方的癌症疫苗為焦點，以美國市場為中心進行全球癌症市場的統計與疫苗開發之簡介，包含2015年為止的預測，概述如下。
第1章 總綱
第2章 導論
- 導論
- 癌症的詳細
- 癌疫苗開發行程表
- 癌治療市場之歷史與發展
- 疫苗種類
- 治療疫苗之種類
- 業界構造
- 人口統計
- 吸煙與肥胖會提高罹癌風險
第3章 子宮頸癌疫苗
第4章 結腸直腸癌疫苗
第5章 肺癌疫苗
第6章 淋巴腫疫苗
第7章 皮膚癌疫苗
第8章 前列腺癌疫苗
第9章 乳癌疫苗
第10章 胃癌疫苗
第11章 腎癌疫苗
第12章 腦瘤疫苗
第13章 膀胱癌疫苗
第14章 卵巣癌疫苗
第15章 白血病疫苗
第16章 癌疫苗對市場造成影響之課題與動向
- 導論
- 早期發線與監測檢査
- 單複製抗體與治療用疫苗
- 政治的、社會的壓力
- 安全性
- 保險與償還問題
- 個別化醫療
- 藥物基因組學
- 疫苗戰略
- 影響對癌疫苗創藥的投資的經濟動向
第17章 市場預測
- 概要
- 市場規模與預測
- 預防疫苗與治療用疫苗市場規模
- 市場與競爭分析
第18章 癌疫苗製造商簡介
附錄
Abstract
Kalorama has been researching and examining the development of cancer vaccines
for seven years. In April 2010, the cancer vaccine market experienced one of
the biggest achievements in the therapeutic vaccine treatment of cancer - the
approval of the prostate cancer vaccine PROVENGE (TM). This, in addition to
the success of cervical cancer vaccine products, has created a viable market
for what was merely a speculative area just one decade ago. Even with
achievements for some companies, numerous vaccines with apparently strong
prospects have been hit by developmental delays and failures. These include
CancerVax' s Canvaxin, Aphton' s Insegia, Progenics' GMK vaccine, and Biomira' s
Theratope. Despite setbacks many developers are hopeful of a turnaround. With
a couple prophylactic vaccines for cervical cancer on the market, a few select
therapeutic vaccine approvals and several therapeutic vaccines on a promising
path to commercialization, the market could see a surge of regulatory activity
and an influx of market opportunities.
This Kalorama Information report - Emerging Cancer Vaccines: Forecasts,
Developments and Pipeline Analysis - focuses on both preventive and
therapeutic cancer vaccines in development. The following cancers for which
there are vaccines in development or where there is a potential are profiled:
- Cervical
- Colon/Rectal
- Lung
- Lymphoma
- Melanoma
- Prostate
- Breast
- Gastrointestinal
- Renal
- Brain
- Bladder
- Ovarian
- Leukemia
The report includes statistical information for cancers by type worldwide,
with special emphasis on the U.S. market. Specifically, cancers where there is
current vaccines development are profiled. Each market segment provides an
overview, descriptions of products available or in development, market
estimates and forecasts for 2010-2015, and competitive analysis of leading
developers for 2015.
The report also includes current issues and trends affecting the industry.
This area of medicine is a new frontier and many of the issues that face the
cancer vaccine market are novel. However, this is a very promising area of
medicine, which will continue to assist in the fight against cancer.
Issues and trends discussed in The Emerging Cancer Vaccine Market include:
- Early Detection and Screening
- Monoclonal Antibodies and Therapeutic Vaccines
- Safety Concerns
- Insurance and Reimbursement Issues
- Personalized Medicine
- Pharmacogenomics
- Vaccine Strategies
- Economic Conditions and Vaccine Discovery
The information for this report was gathered using both primary and secondary
research including comprehensive research of secondary sources such as company
literature, databases, investment reports, and medical and business journals.
Telephone interviews and email correspondence were the primary method of
gathering information.
For the purpose of this study Kalorama Information conducted interviews with
key industry officials, consultants, health care providers, and government
personnel. These sources were the primary basis in gathering information
specifically relating to revenue and market share data presented in this
report. Specific interviews with pharmaceutical company representatives
included marketing directors, division managers, and development
representatives.
All market data pertains to the world market at the manufacturers' level. The
years outlined in this study include projected markets for 2010 thru 2015.
Compound annual growth rates (CAGRs) are provided for the 2010-2015 for each
vaccine segment covered. Competitive analysis is provided for the year 2015
for the developing and emerging market. The projected competitive analysis for
2015 was based on products in late stage development, probability of approval
and marketing, and demographic trends.
Several companies have promising research and development activities for
cancer vaccines. Additionally, many companies are in early stage development
with a focused effort on providing favorable results in treating cancer. Many
of these companies are:
- Accentia
- Antigenics
- AVAX
- Dendreon
- GlaxoSmithKline
- Merck & Co.
- Northwest Biotherapeutics
- Oncothyreon
- Vaccinogen
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Disease Burden
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
CHAPTER TWO: INTRODUCTION
- Introduction
- Cancer Descriptions
- Timeline of Cancer Vaccine Developments
- History and Growth of the Cancer Treatment Market
- Types of Vaccines
- Antigen/Adjuvant Vaccines
- Whole Cell Tumor Vaccines
- Dendritic Cell (DC) Vaccines
- Viral Vectors and DNA Vaccines
- Idiotype Vaccines
- Types of Therapeutic Vaccines
- Patient-Specific Vaccines
- Prostate Specific Antigen
- Sialyl Tn
- Heat Shock Proteins
- Ganglioside Molecules
- Carcinoembryonic Antigen (CEA)
- MART-1
- Tyrosinase
- Adjuvants
- Industry Structure
- Demographics and Statistics
- Growing and Aging Population
- Tobacco Use and Obesity Increases Cancer Risk
- Tobacco Use
- Obesity
- Life Expectancy and Cancer
CHAPTER THREE: CERVICAL CANCER VACCINES
- Overview
- Description of Vaccines on the Market
- Gardasil/Silgard
- Cervarix
- Description of Vaccines in Development
- V503
- RG3484
- PV701
- Lovaxin C
- VGX-3100
- CA-9
- Market Summary
- Current and Potential Competitors and Analysis, 2015
CHAPTER FOUR: COLON/RECTAL CANCER VACCINES
- Overview
- Description of Vaccines on the Market
- Description of Vaccines in Development
- OncoVAX
- TroVAX
- CEA VRP Vaccine (AVX701)
- IMA910
- CDX-1307
- Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
- MKC1106-PP
- GI-4000
- GVAX
- Oncophage
- CRS-207
- Lapuleucel-T
- Market Summary
- Potential Competitors and Analysis, 2015
CHAPTER FIVE: LUNG CANCER VACCINES
- Overview
- Description of Vaccines in Development
- Lucanix
- MAGE-A3 Peptide
- Stimuvax
- EGF Cancer Vaccine
- HyperAcute Lung
- GI-4000
- Oncophage
- TG 4010
- LungVAX
- Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
- DCVax-Lung
- Market Summary
- Potential Competitors and Analysis, 2015
CHAPTER SIX: LYMPHOMA VACCINES
- Overview
- Description of Vaccines in Development
- BiovaxID
- MyVax
- Market Summary
- Potential Competitors and Analysis, 2015
CHAPTER SEVEN: MELANOMA VACCINES
- Overview
- Description of Vaccines on the Market
- Description of Vaccines in Development
- MVAX
- Allovectin-7
- MDX-1379 with Combination Treatment MDX-010
- Oncophage
- MAGE-A3 ASCI
- ALVAC Vaccine
- HyperAcute Melanoma
- Market Summary
- Potential Competitors and Analysis, 2015
CHAPTER EIGHT: PROSTATE CANCER VACCINES
- Overview
- Description of Vaccines on the Market
- Provenge
- Description of Vaccines in Development
- DCVax-Prostate
- GVAX
- PROSTVAC-VF
- TroVAX
- Onyvax-P
- MVA-BN Prostate
- HyperAcute Prostate
- NeuVax
- MKC1106-PP
- Market Summary
- Potential Competitors and Analysis, 2015
CHAPTER NINE: BREAST CANCER VACCINES
- Overview
- Description of Vaccines in Development
- Stimuvax
- NeuVax
- GVAX
- AVX701 Vaccine
- MVA-BN HER2
- Lapuleucel-T
- CDX-1307-02
- Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
- MKC1106-PP
- Market Summary
CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES
- Overview
- Description of Vaccines in Development
- GI-4000
- HyperAcute Pancreas
- GVAX
- Oncophage
- CDX-1307
- ANZ-100
- DCVax
- Market Summary
CHAPTER ELEVEN: RENAL CANCER VACCINES
- Overview
- Description of Vaccines on the Market
- Oncophage
- Description of Vaccines in Development
- Oncophage
- Reniale
- TroVAX
- IMA901
- AGS-003
- MDX-1106
- MKC1106-PP
- Market Summary
- Potential Competitors and Analysis, 2015
CHAPTER TWELVE: BRAIN CANCER VACCINES
- Overview
- Glioblastoma
- Neuroblastoma
- Description of Vaccines in Development
- DCVax-Brain
- CDX-110
- GliaAtak
- Oncophage
- Market Summary
CHAPTER THIRTEEN: BLADDER CANCER VACCINES
- Overview
- Description of Vaccines on the Market
- BCG Therapy (OncoTICE- Organon Teknika) (Immucyst-Sanofi Pasteur)(Pacis-
- Shire Pharmaceuticals)
- Description of Vaccines in Development
- CDX-1307
- Market Summary
CHAPTER FOURTEEN: OVARIAN CANCER VACCINES
- Overview
- Description of Vaccines in Development
- Abagovomab
- OVax Autologous Cell Vaccine
- Lapuleucel-T
- Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
- MKC1106-PP
- Market Summary
CHAPTER FIFTEEN: LEUKEMIA VACCINES
- Overview
- Description of Vaccines in Development
- GVAX-Leukemia
- GRNVAC1
- PR1 Peptide Vaccine
- Market Summary
CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
- Introduction
- Early Detection and Screening
- Monoclonal Antibodies and Therapeutic Vaccines
- Political and Social Pressure
- Safety Concerns
- Insurance and Reimbursement Issues
- Personalized Medicine
- Pharmacogenomics
- Vaccine Strategies
- Economic Conditions Affect Investing in Some Cancer Vaccine Discovery
CHAPTER SEVENTEEN THE CANCER VACCINE MARKET: MARKET FORECASTS
- Overview
- Total Market Size and Forecast
- Prophylactic versus Therapeutic Cancer Vaccine Market Size
- Market and Competitor Analysis
CHAPTER EIGHTEEN CANCER VACCINE CORPORATE PROFILES
- Introduction
- Accentia Biopharmaceuticals, Inc.
- Antigenics, Inc.
- Avax Technologies, Inc.
- Dendreon Corporation
- GlaxoSmithKline plc
- Merck & Company, Inc.
- Northwest Biotherapeutics, Inc.
- Oncothyreon, Inc
- Vaccinogen, Inc.
APPENDIX: COMPANY NAMES AND ADDRESSES
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets,
2007-2015
- Figure 1-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine
Markets, 2007-2015
- Figure 1-2 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets
by Percent and Vaccine Indication, 2015
CHAPTER TWO: INTRODUCTION
- Table 2- Significant Cancer Vaccine Approvals, 2000-201
- Table 2-2 World Cancer Incidence by Selected Types of Cancer, 2010 and
2020, all races, both sexe
- Figure 2-1 Estimated and Projected World Cancer Incidence by Selected
Types of Cancer, 2010 and 2020
- Table 2-3 Total Cancer Incidence by Sex and Country, 2010 Estimates
- Figure 2-2 Total Cancer Incidence by Sex and Country, 2010 Estimates
- Table 2-4 World Population by Selected Geographical Region, 2010 - 2050
- Figure 2-3 World Population by Selected Geographical Region, 2010-2050
- Table 2-5 Percent Population Over 65 by Year and Region, 2010-2050
- Figure 2-4 Estimated World Population by Age, 2010 and 2050
- Table 2-6 Percent of Smokers by Country
- Figure 2-5 Average Percent of Smokers Worldwide in Developed Regions
- Table 2-7 Estimated Obesity by Country 2009 Estimates
- Figure 2-6 Estimated Obesity by Country as a Portion of Total Population
2009 Estimates
- Figure 2-7 Increases in Obesity by Country - 2007 and 2009 Figures
- Table 2-8 Life Expectancy at Birth by Selected Countries, 2006
- Figure 2-8 United States Average Years of Life Lost Per Person Dying of
Cancer, All Races, Both Sexes, 2006
- Figure 2-9 United States Estimated Person-Years of Life Lost Due to
Cancer, All Races, Both Sexes, 2006
- Figure 2-10 United States Person-Years of Life Lost Due to Major Causes of
Death, All Races, Both Sexes, 2006
CERVICAL CANCER VACCINES
- Table 3-1 Estimated World Incidence of Cervical Cancer by Country, 2010
- Figure 3-1 Estimated World Incidence of Cervical Cancer by Country, 2010
- Table 3-2 Cervical Cancer Vaccines Approved and in the Pipeline
- Table 3-3 The Developing Cervical Cancer Vaccine Market, 2007-2015
- Figure 3-2 The Developing Cervical Cancer Vaccine Market, 2007-2015
- Table 3-4 The Developing Cervical Cancer Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2015
- Figure 3-3 The Developing Cervical Cancer Vaccine Market, Leading
Suppliers Shares by Market Revenues, Projected 2015
- Figure 3-4 Product Sales by Year for Cervical Cancer Vaccines, 2007-2015
COLON/RECTAL CANCER VACCINES
- Table 4-1 Estimated World Incidence of Colon/Rectal Cancer by Country, 2010
- Figure 4-1 Estimated World Incidence of Colon/Rectal Cancer by Country,
2010
- Table 4-2 Colon/Rectal Cancer Vaccines in the Pipeline
LUNG CANCER VACCINES
- Table 5-1 TYPES OF PRIMARY LUNG CANCER
- Table 5-2 Estimated World Incidence of Lung Cancer by Country, 2010
- Figure 5-1 Estimated World Incidence of Lung Cancer by Country, 2010
- Table 5-3 Lung Cancer Vaccines in the Pipeline
LYMPHOMA VACCINES
- Table 6-1 CLASSIFICATION OF NON-HODGKIN' S LYMPHOMAS
- Table 6-2 Estimated World Incidence of Lymphoma by Country, 2010
- Figure 6-1 Estimated World Incidence of Lymphoma by Country, 2010
- Table 6-3 Lymphoma Vaccines in the Pipeline
MELANOMA VACCINES
- Table 7-1 MALIGNANT CONDITIONS OF THE SKIN
- Table 7-2 Estimated World Incidence of Melanoma by Country, 2010
- Figure 7-1 Estimated World Incidence of Melanoma by Country, 2010
- Table 7-3 Melanoma Vaccines in the Pipeline
- Table 7-3 (continued) Melanoma Vaccines in the Pipeline
- Table 7-4 The Developing Melanoma Vaccine Market, 2007-2015
- Figure 7-2 The Developing Melanoma Vaccine Market, 2007-2015
- Table 7-5 The Developing Melanoma Vaccine Market, Leading Suppliers Shares
by Market Revenues, Projected 2015
- Figure 7-3 The Developing Melanoma Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2015
- Figure 7-4 Product Sales by Year for Developing Melanoma Vaccines,
2007-2015
PROSTATE CANCER VACCINES
- Table 8-1 Estimated World Incidence of Prostate Cancer by Country, 2010
- Figure 8-1 Estimated World Incidence of Prostate Cancer by Country, 2010
- Table 8-2 Prostate Cancer Vaccines in the Pipeline
- Table 8-2 (continued) Prostate Cancer Vaccines in the Pipeline
- Table 8-3 The Emerging Prostate Cancer Vaccine Market, 2010-2015
- Figure 8-2 The Emerging Prostate Cancer Vaccine Market, 2010-2015
- Table 8-4 The Emerging Prostate Cancer Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2015
- Figure 8-3 The Emerging Prostate Cancer Vaccine Market, Leading Suppliers
Shares by Market Revenues, Projected 2015
- Figure 8-4 Anticipated Product Sales by Year for Emerging Prostate
Vaccines, 2010-2015
BREAST CANCER VACCINES
- Table 9-1 Estimated World Incidence of Breast Cancer by Country, 2010
- Figure 9-1 Estimated World Incidence of Breast Cancer by Country, 2010
- Table 9-2 Breast Cancer Vaccines in the Pipeline
GASTROINTESTINAL CANCER VACCINES
- Table 10-1 Estimated World Incidence of Gastrointestinal Cancer by
Country, 2010
- Figure 10-1 Estimated World Incidence of Gastrointestinal Cancer by
Country, 2010
- Table 10-2 Gastrointestinal Cancer Vaccines in the Pipeline
RENAL CANCER VACCINES
- Table 11-1 Estimated World Incidence of Renal Cancer by Country, 2010
- Figure 11-1 Estimated World Incidence of Renal Cancer by Country, 2010
- Table 11-2 Renal Cancer Vaccines in the Pipeline
BRAIN CANCER VACCINES
- Table 12-1 Estimated World Incidence of Brain Cancer by Country, 2010
- Figure 12-1 Estimated World Incidence of Brain Cancer by Country, 2010
- Table 12-2 Brain Cancer Vaccines in the Pipeline
BLADDER CANCER VACCINES
- Table 13-1 Estimated World Incidence of Bladder Cancer by Country, 2010
- Figure 13-1 Estimated World Incidence of Bladder Cancer by Country, 2010
- Table 13-2 Bladder Cancer Vaccines in the Pipeline
OVARIAN CANCER VACCINES
- Table 14-1 Estimated World Incidence of Ovarian Cancer by Country, 2010
- Figure 14-1 Estimated World Incidence of Ovarian Cancer by Country, 2010
- Table 14-2 Ovarian Cancer Vaccines in the Pipeline
LEUKEMIA VACCINES
- Table 15-1 TYPES OF LEUKEMIA
- Table 15-2 Estimated World Incidence of Leukemia by Country, 2010
- Figure 15-1 Estimated World Incidence of Leukemia Cancer by Country, 2010
- Table 15-3 Leukemia Vaccines in the Pipeline
ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
- Table 16-1 Cancer Detection Tests
- Table 16-2 Early Safety Statistics Concerning HPV Vaccination
THE CANCER VACCINE MARKET: MARKET FORECASTS
- Table 17-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine
Markets, 2007-2015
- Figure 17-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine
Markets, 2007-2015
- Figure 17-2 Cancer Vaccines: Developing and Emerging Cancer Vaccine
Markets by Percent and Vaccine Indication, 2015
- Figure 17-3 Cancer Vaccines: Prophylactic and Therapeutic Cancer Vaccine
Markets, 2007-2015 208
- Figure 17-2 Cancer Vaccines: Prophylactic and Therapeutic Cancer Vaccine
Markets by Percent, 2015
CANCER VACCINE CORPORATE PROFILE: COMPANY NAMES AND ADDRESSES
|
 |
